SCHEMBL3813757

SCHEMBL3813757

NS(=O)(=O)n1cnc2cnc3ccccc3c21

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.41
GAA P10253 2/20 0.39
PKM P14618 1/20 0.39
KDM4E B2RXH2 2/20 0.38
GPR3 P46089 1/20 0.38
HTT P42858 4/20 0.37
ALDH3A1 P30838 3/20 0.37
POLB P06746 1/20 0.37
NOD1 Q9Y239 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TSHR P16473 2/20 0.37
HSD17B10 Q99714 2/20 0.36
HPGD P15428 1/20 0.36
GRM5 P41594 2/20 0.36
USP2 O75604 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3817799 0.79 CA12 (0.38) ERN1GAAPKMKDM4EGPR3
SCHEMBL4703998 0.76 KDM4E (0.42) ERN1KDM4EGPR3L3MBTL1HSD17B10
SCHEMBL830432 0.74 ALDH3A1 (0.57) GAAHTTALDH3A1POLBNOD1
SCHEMBL7102791 0.74 TLR7 (0.54) POLBLMNA
SCHEMBL5092806 0.73 KDM4E (0.42) ERN1KDM4EGPR3HSD17B10HPGD
SCHEMBL204996 0.73 KDM4E (0.42) ERN1GAAKDM4EGPR3TSHR
SCHEMBL5528658 0.73 KDM4E (0.42) KDM4EGPR3HSD17B10HPGDGRM5
SCHEMBL5823463 0.73 KDM4E (0.42) ERN1GAAPKMKDM4EGPR3
SCHEMBL1486425 0.71 KDM4E (0.41) ERN1GAAPKMKDM4EGPR3
SCHEMBL4361065 0.71 PDE4A (0.37) ERN1GAAPKMHTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1642580-B1 Sulfonamide substituted imidazoquinolines COLEY PHARM GROUP INC (US) 2009-08-19 EP disclosed
EP-1638566-A4 SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2009-03-25 EP disclosed
US-7199131-B2 Sulfonamide and sulfamide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-04-03 US disclosed
EP-1198233-B1 SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2006-08-16 EP disclosed
US-20060106052-A1 METHOD OF USING SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY 2006-05-18 US disclosed
US-7030131-B2 Sulfonamide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2006-04-18 US disclosed
EP-1642580-A1 Sulfonamide substituted imidazoquinolines 3M Innovative Properties Company (US) 2006-04-05 EP disclosed
EP-1638566-A2 SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2006-03-29 EP disclosed
US-20050197358-A1 Sulfonamide and sulfamide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2005-09-08 US disclosed
US-6924293-B2 Sulfonamide and sulfamide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-08-02 US disclosed
US-20040204438-A1 Sulfonamide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-10-14 US disclosed
US-6800624-B2 INDUCE BIOSYNTHESIS OF CYTOKINES; IMMUNE RESPONSE MODIFIERS; TREATMENT OF VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY 2004-10-05 US disclosed
US-20040132762-A1 Sulfonamide and sulfamide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-07-08 US disclosed
US-20040106638-A1 Sulfonamide and sulfamide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-06-03 US disclosed
US-20040029877-A1 Sulfonamide and sulfamide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-02-12 US disclosed
US-6677349-B1 INDUCE CYTOKINE BIOSYNTHESIS; ANTICARCINOGENIC AGENTS, VIRICIDES 3M INNOVATIVE PROPERTIES COMPANY 2004-01-13 US disclosed
EP-1198233-A4 SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2002-07-24 EP disclosed
EP-1198233-A1 SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2002-04-24 EP disclosed
US-6331539-B1 INDUCE BIOSYNTHESIS OF INTERFERON ALPHA IN ANIMALS 3M INNOVATIVE PROPERTIES COMPANY 2001-12-18 US disclosed
WO-2000076519-A1 SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029877-A1 Sulfonamide and sulfamide substituted imidazoquinolines IFNG, IRF3, EIF2AK2 ERN1 1679/4885GAA 2938/4885PKM 3412/4885
US-20060106052-A1 METHOD OF USING SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES IFNG, MYD88, IL2 ERN1 1737/4885GAA 2734/4885PKM 2615/4885
US-20050197358-A1 Sulfonamide and sulfamide substituted imidazoquinolines IFNG, IRF3, EIF2AK2 ERN1 1679/4885GAA 2938/4885PKM 3412/4885
US-20040204438-A1 Sulfonamide substituted imidazoquinolines IRF3, IFNG, EIF2AK2 ERN1 1056/4885GAA 3392/4885PKM 3242/4885
US-20040132762-A1 Sulfonamide and sulfamide substituted imidazoquinolines IFNG, IRF3, EIF2AK2 ERN1 1679/4885GAA 2938/4885PKM 3412/4885
US-20040106638-A1 Sulfonamide and sulfamide substituted imidazoquinolines IFNG, IRF3, EIF2AK2 ERN1 1679/4885GAA 2938/4885PKM 3412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.